VJHemOnc Podcast

Dr. John G, an expert in CAR-T therapy, discusses the challenges and potential of CAR-T therapy in CLL, including the ideal timing for treatment, combining therapies for better outcomes, and the significance of CAR-T cell persistence in CLL.

Leading experts discuss the impact of mutations in myelodysplastic syndrome (MDS) and the importance of understanding precursor states such as clonal cytopenia of undetermined significance (CCUS) and clonal hematopoiesis of indeterminate potential (CHIP). They explore the evolution of clonal hematopoiesis over time, including the impact of autologous stem cell transplantation and DDR mutations. This podcast highlights the challenges of evaluating treatment outcomes and the need to better understand selection pressures and interventions for expanding pre-existing clonal hematopoiesis.

Experts discuss the challenges and future applications of T-cell engagers in multiple myeloma, including combining them with CAR-T cell therapies, treating high-risk patients, and the potential of off-the-shelf allogenic CAR-T cell therapy. The podcast also covers the cost considerations and efficacy of CAR-T cell therapy.

Experts discuss the current state and challenges of high-risk MDS treatment, the potential of novel therapies and combination approaches, including apronetopopt and XPR1 targeting. They touch on patient characteristics, biomarkers, and the need for longer-lasting responses. The podcast provides hope for improved outcomes and highlights ongoing studies with promising drugs.

The podcast discusses the importance of investigating patient-reported outcomes in CAR-T recipients. The guests highlight the significance of assessing patient-reported outcomes in individuals receiving CAR T therapy, sharing findings from a pilot study that utilized patient surveys and Fitbit data collection. They also discuss the lack of patient-reported outcomes research in the field and share findings from a study conducted in 2017 that revealed patients' symptomatic toxicities and neurotoxicity experiences.

Experts discuss key updates from the lymphoma and myeloma sessions at the iwCAR-T meeting, including CAR-T therapy in second-line DLBCL, strategies to overcome challenges in myeloma, patient selection for CAR-T therapy, and more.

Experts John DiPersio and Saar Gill discuss challenges and future outlooks of CAR-T therapy in AML. They explore CAR-NK therapy, patient response, and NK-cell transduction. They also discuss the potential use of macrophages and new approaches to CAR-T therapy in AML, including CRISPR gene editing and targeting multiple antigens.

Leading expert in CAR-T therapy in lymphoma, David Maloney, MD, PhD, discusses the current state of CAR-T therapy in lymphoma, including clinical trial updates and the potential of CAR-T therapy in high-risk patients. The importance of patient selection, removing mantle salomfoma cells, and exploring the effectiveness in follicular lymphoma are highlighted.

Advances in myeloma treatment, including novel immunotherapies, were discussed at the EHA 2022. Topics covered include the determination trial, follow-up duration controversy, role of bispecific antibodies, immunomodulatory drugs and CAR T cells, and updates on antibody-drug conjugates.

Experts discuss updates in classification and risk stratification in MDS, including the novel IPSS-M and the MDS Clinical Research Consortium Molecular Prognostic Tool. They explore TP-53 mutant group, germline predisposition genes, and the importance of genetic sequencing in prognosis and monitoring minimal residual disease in MDS.